Introduction to KEYNOTE-100 trial of pembrolizumab in advanced recurrent ovarian cancer
Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer
ESMO 2016: Introduction to press briefs and presidential symposia
Immune adverse events of checkpoint inhibitors
How can germline mutations distinguish risk for lethal and indolent prostate cancer?